Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

被引：13

作者：

Colevas, D. A. ^{[1
]}

Misiukiewicz, K. ^{[2
]}

Pearson, A. T. ^{[3
]}

Fayette, J. ^{[4
]}

Bauman, J. R. ^{[5
]}

Cupissol, D. ^{[6
]}

Saada-Bouzid, E. ^{[7
]}

Adkins, D. R. ^{[8
]}

Marie, D. B. ^{[9
]}

Cornen, S. L. ^{[9
]}

Andre, P. ^{[9
]}

Carrette, F. ^{[9
]}

Rotolo, F. ^{[9
]}

Boyer Chammard, A. ^{[9
]}

Cohen, R. B. ^{[10
]}

机构：

[1] Stanford Canc Ctr, Med Oncol, Stanford, CA 94305 USA

[2] Mt Sinai Hosp, Med Oncol, New York, NY 10029 USA

[3] Univ Chicago, Med Oncol, Chicago, IL 60637 USA

[4] Ctr Leon Berard, Med Oncol, Lyon, France

[5] Fox Chase Canc Ctr Main Campus, Dept Hematol Oncol, Philadelphia, PA 19140 USA

[6] Inst Canc Montpellier, Med Oncol, Montpellier, France

[7] Ctr Antoine Lacassagne, Med Oncol, Nice, France

[8] Washington Univ, Med Oncol, Sch Med, St Louis, MO 63130 USA

[9] Innate Pharma, Res & Dev, Marseille, France

[10] Abramson Canc Ctr, Ctr Head & Neck Canc, Philadelphia, PA USA

来源：

关键词：

D O I：

10.1016/j.annonc.2021.10.142

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

123MO

引用

页码：S1432 / S1432

页数：1